Document is current
Any future updates will be listed below
-
Authors
Kajiwara, Yoshinori
Tazawa, Hiroshi
Yamada, Motohiko
Kanaya, Nobuhiko
Fushimi, Takuro
Kikuchi, Satoru
Kuroda, Shinji
Ohara, Toshiaki
Noma, Kazuhiro
Yoshida, Ryuichi
Umeda, Yuzo
Urata, Yasuo
Kagawa, Shunsuke
Fujiwara, Toshiyoshi
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP16K10596, JP16H05416)
Japan Agency for Medical Research and Development (17ck0106285h0001)
- License Information
-
More Information
Article History
Received: 12 October 2022
Accepted: 18 November 2022
First Online: 27 November 2022
Declarations
:
: Y. Urata is President & CEO of Oncolys BioPharma Inc. H. Tazawa and T. Fujiwara are consultants of Oncolys BioPharma Inc. The other authors have no potential conflicts of interest to disclose.
: Y. Urata is President & CEO of Oncolys BioPharma Inc. H. Tazawa and T. Fujiwara are consultants of Oncolys BioPharma Inc. The other authors have no potential conflicts of interest to disclose.
